X

Trial Profile

Assessing the safety of ES-3000 and ASTX727 in patients with myelodysplasia (MYDAS-T)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cedazuridine/decitabine (Primary) ; ES-3000 (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; Therapeutic Use
Acronyms MYDAS-T; MYDAS-T Run ES IN

Most Recent Events

20 Jun 2024 According to an Escend Pharmaceuticals media release, data from this study were presented at European Hematology Association (EHS) in Madrid, Spain.
20 Jun 2024 Status changed from not yet recruiting to recruiting, according to an Escend Pharmaceuticals media release.
20 Jun 2024 Results presented in an Escend Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com